Cover Image
市場調查報告書

EpiCast Report:大腸躁鬱症(IBS)的流行病學預測

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 317757
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:大腸躁鬱症(IBS)的流行病學預測 EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023
出版日期: 2014年10月27日 內容資訊: 英文 49 Pages
簡介

大腸躁鬱症(IBS),是具有腹部的不舒服和疼痛,膨脹感,排便習慣改變的特徵,慢性復發的腸胃障礙。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)大腸躁鬱症(IBS)和確診的患者數,從2013年的4,077萬人,預計今後10年增加3.9%到4,236萬人。

本報告提供全球主要7個國家的大腸躁鬱症(IBS)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法 - IBS的總患者數
    • 預測的前提條件與手法 - IBS的亞型區分
  • IBS的流行病學預測
    • IBS的整體患者數
    • IBS的整體患者數(各年齡)
    • IBS的整體患者數(性別)
    • IBS的整體患者數(年齡標準化)
    • IBS的整體患者數(各臨床子類型)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER068-14

Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.

IBS is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient's quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. Several factors, including psychological disorders, stress, environmental factors, infection, and inflammation have been reported to play a role in the pathogenesis of IBS, however, their exact role remains to be clarified.

GlobalData epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.

GlobalData's epidemiological analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; GlobalData epidemiologists segmented IBS by sex, age, and subclassification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets.

Scope

  • The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
  • The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of IBS
    • 3.4.4. Forecast Assumptions and Methods - IBS Subtype Segmentations
  • 3.5. Epidemiological Forecast for IBS (2013-2023)
    • 3.5.1. Total Prevalent Cases of IBS
    • 3.5.2. Age-Specific Total Prevalent Cases of IBS
    • 3.5.3. Sex-Specific Total Prevalent Cases of IBS
    • 3.5.4. Age-Standardized Total Prevalence of IBS
    • 3.5.5. Total Prevalent Cases of IBS by Clinical Subtype
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for IBS
  • Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies
  • Table 3: Total Prevalence (%) of IBS in the 7MM, as Reported in Epidemiological Studies
  • Table 4: Total Prevalence (%) of IBS in the US, as Reported in Epidemiological Studies
  • Table 5: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of IBS
  • Table 6: 7MM, Sources of IBS Subtype Data Used to Forecast the Total Prevalent Cases of IBS by Subtype
  • Table 7: 7MM, Total Prevalent Cases of IBS, Ages ≥10 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 8: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N (Row %), 2013
  • Table 9: 7MM, Sex-Specific Prevalent Cases of IBS, Ages ≥10 Years, N (Row %), 2013
  • Table 10: 7MM Total Prevalent Cases of IBS, N (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of IBS Ages ≥10 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N, 2013
  • Figure 3: 7MM, Sex-Specific Total Prevalent Cases of IBS, Ages ≥10 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of IBS (%), Ages ≥10 Years, by Sex, 2013
  • Figure 5: 7MM Total Prevalent Cases of IBS (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013
Back to Top